The molecular basis of IgA nephropathy

Molecular and Genetic Basis of Renal Disease

Volumn , Issue , 2008, Pages 481-497

  Hsu, Stephen I Hong ^a,b   Feehally, John ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882561582     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0252-9.50031-8     Document Type: Chapter

References (180)

1. Floege J, Burg M, Kliem V Recurrent IgA nephropathy after renal transplantation. Semin Nephrol 2004, 24:287-291.
2. Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc 1987, 19:2208-2209.
3. Sanfilippo F, Croker BP, Bollinger RR Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 1982, 33:370-376.
4. Viertel A, Weidmann E, Rickerts V, et al. Renal involvement in HIV-infection. Results from the Frankfurt AIDS Cohort Study (FACS) and a review of the literature. Eur J Med Res 2000, 5:185-198.
5. Davin JC, Ten Berge IJ, Weening JJ What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis?. Kidney Int 2001, 59:823-834.
6. Kerr MA The structure and function of human IgA. Biochem J 1990, 271:285-296.
7. Johansen FE, Braathen R, Brandtzaeg P Role of J chain in secretory immunoglobulin formation. Scand J Immunol 2000, 52:240-248.
8. Russell MW, Kilian M, Lamm ME Biological activities of IgA. Mucosal Immunology 1999, 225-240. Academic Press, San Diego, CA. 2nd ed. J. Mestecky, J. Bienenstock, J. McGhee (Eds.).
9. Mestecky J, Russell MW, Elson CO Intestinal IgA: Novel views on its function in the defence of the largest mucosal surface. Gut 1999, 44:2-5.
10. Layward L, Allen AC, Hattersley JM, et al. Low antibody affinity restricted to the IgA isotype in IgA nephropathy. Clin Exp Immunol 1994, 95:35-41.
11. Lycke N T cell and cytokine regulation of the IgA response. Chem Immunol 1998, 71:209-234.
12. Defrance T, Vanbervliet B, Briere F, et al. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992, 175:671-682.
13. Fujihashi K, Kweon MN, Kiyono H, et al. A T cell/B cell/epithelial cell internet for mucosal inflammation and immunity. Springer Semin Immunopathol 1997, 18:477-494.
14. Abreu-Martin MT, Targan SR Regulation of immune responses of the intestinal mucosa. Crit Rev Immunol 1996, 16:277-309.
15. Brandtzaeg P, Farstad IN, Johansen FE, et al. The B-cell system of human mucosae and exocrine glands. Immunol Rev 1999, 171:45-87.
16. Wiedle G, Dunon D, Imhof BA Current concepts in lymphocyte homing and recirculation. Crit Rev Clin Lab Sci 2001, 38:1-31.
17. Pabst R, Binns RM In vivo labelling of the spleen and mesenteric lymph nodes with fluorescein isothiocyanate for lymphocyte migration studies. Immunology 1981, 44:321-329.
18. Pabst R, Reynolds JD Peyer's patches export lymphocytes throughout the lymphoid system in sheep. J Immunol 1987, 139:3981-3985.
19. Alley CD, Kiyono H, McGhee JR Murine bone marrow IgA responses to orally administered sheep erythrocytes. J Immunol 1986, 136:4414-4419.
20. Simecka JW Mucosal immunity of the gastrointestinal tract and oral tolerance. Adv Drug Deliv Rev 1998, 34:235-259.
21. Roncarolo MG, Bacchetta R, Bordignon C, et al. Type 1 T regulatory cells. Immunol Rev 2001, 182:68-79.
22. Ke Y, Pearce K, Lake JP, et al. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 1997, 158:3610-3618.
23. Fujihashi K, McGhee JR, Kweon MN, et al. Gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med 1996, 183:1929-1935.
24. Chao CC, Sandor M, Dailey MO Expression and regulation of adhesion molecules by gamma delta T cells from lymphoid tissues and intestinal epithelium. Eur J Immunol 1994, 24:3180-3187.
25. Lim SP, Leung E, Krissansen GW The beta7 integrin gene (Itgb-7) promoter is responsive to TGF-beta1: Defining control regions. Immunogenetics 1998, 48:184-195.
26. van Egmond M, van Garderen E, van Spriel AB, et al. FcalphaRI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000, 6:680-685.
27. Rifai A, Schena FP, Montinaro V, et al. Clearance kinetics and fate of macromolecular IgA in patients with IgA nephropathy. Lab Invest 1989, 61:381-388.
28. Rifai A, Fadden K, Morrison SL, et al. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med 2000, 191:2171-2182.
29. Grossetete B, Launay P, Lehuen A, et al. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: Evidence for a negative regulatory role of serum IgA. Kidney Int 1998, 53:1321-1335.
30. Feehally J Immune mechanisms in glomerular IgA deposition. Nephrol Dial Transplant 1988, 3:361-378.
31. Harada T, Hobby P, Courteau M, et al. Charge distribution of plasma IgA in IgA nephropathy. Clin Exp Immunol 1989, 77:211-214.
32. Monteiro RC, Chevailler A, Noel LH, et al. Serum IgA preferentially binds to cationic polypeptides in IgA nephropathy. Clin Exp Immunol 1988, 73:300-306.
33. Lam CW, Chui SH, Leung NW, et al. Light chain ratios of serum immunoglobulins in disease. Clin Biochem 1991, 24:283-287.
34. Allen A, Feehally J IgA glycosylation in IgA nephropathy. Adv Exp Med Biol 1998, 435:175-183.
35. Allen AC Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy. J Nephrol 1999, 12:76-84.
36. Mestecky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993, 104:172-182.
37. Allen AC, Bailey EM, Barratt J, et al. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 1999, 10:1763-1771.
38. Hiki Y, Iwase H, Kokubo T, et al. Association of asialogalactosyl beta 1-3N-acetylgalactosamine on the hinge with a conformational instability of Jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy. J Am Soc Nephrol 1996, 7:955-960.
39. Hiki Y, Tanaka A, Kokubo T, et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998, 9:577-582.
40. Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001, 59:1077-1085.
41. Leung JC, Tang SC, Chan DT, et al. Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy. J Clin Lab Anal 2002, 16:11-19.
42. Boehm MK, Woof JM, Kerr MA, et al. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: A study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 1999, 286:1421-1447.
43. Moura IC, Arcos-Fajardo M, Leroy V, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferring receptor in IgA nephropathy. J Am Soc Nephrol 2004, 15:622-634.
44. Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998, 9:2048-2054.
45. Xu LH, Zhao MH Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 2005, 68:167-172.
46. O'Donoghue DJ, Feehally J Autoantibodies in IgA nephropathy. Contrib Nephrol 1995, 111:93-103.
47. Layward L, Allen AC, Hattersley JM, et al. Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass. Nephrol Dial Transplant 1993, 8:25-28.
48. van den Wall Bake AW, Beyer WE, Evers-Schouten JH, et al. Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies. J Clin Invest 1989, 84:1070-1075.
49. Layward L, Allen AC, Harper SJ, et al. Increased and prolonged production of specific polymeric IgA after systemic immunization with tetanus toxoid in IgA nephropathy. Clin Exp Immunol 1992, 88:394-398.
50. Fortune F, Courteau M, Williams DG, et al. T and B cell responses following immunization with tetanus toxoid in IgA nephropathy. Clin Exp Immunol 1992, 88:62-67.
51. Kokubo T, Hashizume K, Iwase H, et al. Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant 2000, 15:28-33.
52. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999, 104:73-81.
53. Roccatello D, Picciotto G, Coppo R, et al. The fate of aggregated immunoglobulin A injected in IgA nephropathy patients and healthy controls. Am J Kidney Dis 1991, 18:20-25.
54. Leung JC, Tsang AW, Chan LY, et al. Size-dependent binding of IgA to HepG2, U937, and human mesangial cells. J Lab Clin Med 2002, 140:398-406.
55. van Zandbergen G, van Kooten C, Mohamad NK, et al. Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant 1998, 13:3058-3064.
56. Hisano S, Matsushita M, Fujita T, et al. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 2001, 38:1082-1088.
57. Oortwijn BD, van der Boorg PJ, Roos A, et al. A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int 2006, 69:1131-1138.
58. Feehally J, Allen AC Pathogenesis of IgA nephropathy. Ann Med Interne (Paris) 1999, 150:91-98.
59. Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients. Kidney Int 2001, 60:969-973.
60. Leinikki PO, Mustonen J, Pasternack A Immune response to oral polio vaccine in patients with IgA glomerulonephritis. Clin Exp Immunol 1987, 68:33-38.
61. Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999, 33:1049-1057.
62. Ots M, Uibo O, Metskula K, et al. IgA-antigliadin antibodies in patients with IgA nephropathy: The secondary phenomenon?. Am J Nephrol 1999, 19:453-458.
63. Westberg NG, Baklien K, Schmekel B, et al. Quantitation of immunoglobulin-producing cells in small intestinal mucosa of patients with IgA nephropathy. Clin Immunol Immunopathol 1983, 26:442-445.
64. Harper SJ, Pringle JH, Wicks AC, et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 1994, 45:836-844.
65. de Fijter JW, Eijgenraam JW, Braam CA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int 1996, 50:952-961.
66. van den Wall Bake AW, Daha MR, Evers-Schouten J, et al. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: Evidence for the bone marrow as the source of mesangial IgA. Am J Kidney Dis 1988, 12:410-414.
67. Harper SJ, Allen AC, Pringle JH, et al. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 1996, 49:38-42.
68. Layward L, Finnemore AM, Allen AC, et al. Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy. Clin Immunol Immunopathol 1993, 69:306-313.
69. Ichinose H, Miyazaki M, Koji T, et al. Detection of cytokine mRNA-expressing cells in peripheral blood of patients with IgA nephropathy using non-radioactive in situ hybridization. Clin Exp Immunol 1996, 103:125-132.
70. Lai KN, Ho RT, Lai CK, et al. Increase of both circulating Th1 and Th2 T lymphocyte subsets in IgA nephropathy. Clin Exp Immunol 1994, 96:116-121.
71. Ebihara I, Hirayama K, Yamamoto S, et al. Th2 predominance at the single-cell level in patients with IgA nephropathy. Nephrol Dial Transplant 2001, 16:1783-1789.
72. + cells from patients with IgA nephropathy. Kidney Int 1994, 46:862-868.
73. de Caestecker MP, Bottomley M, Telfer BA, et al. Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int 1993, 44:1298-1308.
74. de Fijter JW, Daha MR, Schroeijers WE, et al. Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy. Clin Exp Immunol 1998, 111:429-434.
75. Allen AC, Harper SJ, Feehally J Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995, 100:470-474.
76. Greer MR, Barratt J, Harper SJ, et al. The nucleotide sequence of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant 1998, 13:1980-1983.
77. Allen AC, Topham PS, Harper SJ, et al. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 1997, 12:701-706.
78. Ju T, Cummings RD A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A 2002, 99:16613-16618.
79. Oin W, Zhou O, Ynag LC, et al. Peripheral B lymphocyte beta 1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med 2005, 258:467-477.
80. Smith AC, de Woolff JF, Molyneux K, et al. O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 2006, 17:1192-1199.
81. Pierce-Cretel A, Pamblanco M, Strecker G, et al. Heterogeneity of the glycans O-glycosidically linked to the hinge region of secretory immunoglobulins from human milk. Eur J Biochem 1981, 114:169-178.
82. Smith AC, Molyneux K, Feehally J, Barratt J O-glycosylation of serum IgA antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006, 17:3520-3528.
83. Feehally J, Beattie TJ, Brenchley PE, et al. Response of circulating immune complexes to food challenge in relapsing IgA nephropathy. Pediatr Nephrol 1987, 1:581-586.
84. Nagy J, Scott H, Brandtzaeg P Antibodies to dietary antigens in IgA nephropathy. Clin Nephrol 1988, 29:275-279.
85. Rostoker G, Petit-Phar M, Delprato S, et al. Mucosal immunity in primary glomerulonephritis: II. Study of the serum IgA subclass repertoire to food and airborne antigens. Nephron 1991, 59:561-566.
86. Kennel A, Bene MC, Hurault de Ligny B, et al. Serum anti-dextran antibodies in IgA nephropathy. Clin Nephrol 1995, 43:216-220.
87. Rantala I, Collin P, Holm K, et al. Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Kidney Int 1999, 55:2274-2280.
88. Rostoker G, Delchier JC, Chaumette MT Increased intestinal intra-epithelial T lymphocytes in primary glomerulonephritis: A role of oral tolerance breakdown in the pathophysiology of human primary glomerulonephritides?. Nephrol Dial Transplant 2001, 16:513-517.
89. Olive C, Allen AC, Harper SJ, et al. Expression of the mucosal gamma delta T cell receptor V region repertoire in patients with IgA nephropathy. Kidney Int 1997, 52:1047-1053.
90. Buck KS, Foster EM, Watson D, et al. Expression of T cell receptor variable region families by bone marrow gamma delta T cells in patients with IgA nephropathy. Clin Exp Immunol 2002, 127:527-532.
91. Toyabe S, Harada W, Uchiyama M Oligoclonally expanding gammadelta T lymphocytes induce IgA switching in IgA nephropathy. Clin Exp Immunol 2001, 124:110-117.
92. Batra A, Foster EM, Barratt J, et al. Increased systemic homing T cell numbers in IgA nephropathy. J Am Soc Nephrol 2002, 13:350A.
93. Waldherr R, Rambausek M, Duncker WD, et al. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989, 4:943-946.
94. Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: A repeat biopsy study. Am J Kidney Dis 2002, 39:493-502.
95. Zickerman AM, Allen AC, Talwar V, et al. IgA myeloma presenting as Henoch-Schonlein purpura with nephritis. Am J Kidney Dis 2000, 36:E19.
96. Launay P, Grossetete B, Arcos-Fajardo M, et al. Fc alpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease): Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000, 191:1999-2009.
97. Van Der Boog PJ, De Fijter JW, Van Kooten C, et al. Complexes of IgA with Fc alphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int 2003, 63:514-521.
98. Tomino Y, Endoh M, Nomoto Y, et al. Specificity of eluted antibody from renal tissues of patients with IgA nephropathy. Am J Kidney Dis 1982, 1:276-280.
99. Orfila C, Rakotoarivony J, Manuel Y, et al. Immunofluorescence characterization of light chains in human nephropathies. Virchows Arch A Pathol Anat Histopathol 1988, 412:591-594.
100. Gomez-Guerrero C, Duque N, Egido J Mesangial cells possess an asialoglycoprotein receptor with affinity for human immunoglobulin A. J Am Soc Nephrol 1998, 9:568-576.
101. McDonald KJ, Cameron AJ, Allen JM, et al. Expression of Fc-alpha/mu receptor by human mesangial cells: A candidate receptor for immune complex deposition in IgA nephropathy. Biochem Biophys Res Commun 2002, 290:438-442.
102. Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001, 194:417-425.
103. Haddad E, Moura IC, Arcos-Fajardo M, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schonlein nephritis: Association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003, 14:327-337.
104. Moura IC, Arcos-Fajardo M, Gdoura A, et al. Engagement of transferrin receptor by polymeric IgA1: Evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005, 16:2667-2676.
105. Barratt J, Greer MR, Pawluczyk IZ, et al. Identification of a novel Fcalpha receptor expressed by human mesangial cells. Kidney Int 2000, 57:1936-1948.
106. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, et al. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol 1994, 153:5247-5255.
107. Yan D, Rumbeiha WK, Pestka JJ Experimental murine IgA nephropathy following passive administration of vomitoxin-induced IgA monoclonal antibodies. Food Chem Toxicol 1998, 36:1095-1106.
108. Imasawa T, Utsunomiya Y, Kawamura T, et al. Evidence suggesting the involvement of hematopoietic stem cells in the pathogenesis of IgA nephropathy. Biochem Biophys Res Commun 1998, 249:605-611.
109. Imasawa T, Nagasawa R, Utsunomiya Y, et al. Bone marrow transplantation attenuates murine IgA nephropathy: Role of a stem cell disorder [see comments]. Kidney Int 1999, 56:1809-1817.
110. Stad RK, Bruijn JA, van Gijlswijk-Janssen DJ, et al. An acute model for IgA-mediated glomerular inflammation in rats induced by monoclonal polymeric rat IgA antibodies. Clin Exp Immunol 1993, 92:514-521.
111. Fujii K, Muller KD, Clarkson AR, et al. The effect of IgA immune complexes on the proliferation of cultured human mesangial cells. Am J Kidney Dis 1990, 16:207-210.
112. Chen A, Chen WP, Sheu LF, et al. Pathogenesis of IgA nephropathy: In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion. J Pathol 1994, 173:119-126.
113. Lopez-Armada MJ, Gomez-Guerrero C, Egido J Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: Role of TGF-beta. J Immunol 1996, 157:2136-2142.
114. Peruzzi L, Amore A, Cirina P, et al. Integrin expression and IgA nephropathy: In vitro modulation by IgA with altered glycosylation and macromolecular IgA. Kidney Int 2000, 58:2331-2340.
115. Monteiro RC, Moura IC, Launay P, et al. Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends Mol Med 2002, 8:464-468.
116. Van Dixhoorn MG, Sato T, Muizert Y, et al. Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation [In Process Citation]. Kidney Int 2000, 58:90-99.
117. Lai KN, Tang SC, Guh JY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-β synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 2003, 14:3127-3137.
118. Wang Y, Zhao MH, Li XM, Wan HY Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells. Clin Exp Immunol 2004, 136:168-175.
119. Amore A, Cirina P, Conti G, et al. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001, 12:1862-1871.
120. Coppo R, Amore A Aberrant glycosylation in IgA nephropathy. Kidney Int 2004, 65:1544-1547.
121. Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005, 67:504-513.
122. Matsuda M, Shikata K, Wada J, et al. Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 1998, 80:408-413.
123. Hansch GM The role of complement in mesangial cell damage [Editorial]. Nephrol Dial Transplant 1993, 8:4-5.
124. Endo M, Ohi H, Ohsawa I, et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998, 13:1984-1990.
125. Abe K, Miyazaki M, Koji T, et al. Intraglomerular synthesis of complement C3 and its activation products in IgA nephropathy. Nephron 2001, 87:231-239.
126. Abe K, Miyazaki M, Koji T, et al. Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int 1998, 54:120-130.
127. Moll S, Miot S, Sadallah S, et al. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 2001, 59:160-168.
128. Yoshioka K, Takemura T, Aya N, et al. Monocyte infiltration and cross-linked fibrin deposition in IgA nephritis and Henoch-Schonlein purpura nephritis. Clin Nephrol 1989, 32:107-112.
129. Arima S, Nakayama M, Naito M, et al. Significance of mononuclear phagocytes in IgA nephropathy. Kidney Int 1991, 39:684-692.
130. Li HL, Hancock WW, Dowling JP, et al. Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis. Kidney Int 1991, 39:793-798.
131. Johnson RJ The glomerular response to injury: Progression or resolution?. Kidney Int 1994, 45:1769-1782.
132. Hsu SI, Ramirez SB, Winn MP, et al. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000, 57:1818-1835.
133. Imai H, Nakamoto Y, Asakura K, et al. Spontaneous glomerular IgA deposition in ddY mice: An animal model of IgA nephritis. Kidney Int 1985, 27:756-761.
134. Miyawaki S, Muso E, Takeuchi E, et al. Selective breeding for high serum IgA levels from noninbred ddY mice: Isolation of a strain with an early onset of glomerular IgA deposition. Nephron 1997, 76:201-207.
135. Zhang Z, Kundu GC, Yuan CJ, et al. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 1997, 276:1408-1412.
136. Zheng F, Kundu GC, Zhang Z, et al. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Nat Med 1999, 5:1018-1025.
137. Yong D, Qing WQ, Hua L, et al. Association of uteroglobin G38A polymorphism with IgA nephropathy: A meta-analysis. Am J Kidney Dis 2006, 48:1-7.
138. Launay P, Grossetete B, Arcos-Fajardo M, et al. Fc alpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med 2000, 191:1999-2009.
139. van der Boog PJ, van Kooten C, van Zandbergen G, et al. Injection of recombinant Fc alpha RI/CD89 in mice does not induce mesangial IgA deposition. Nephrol Dial Transplant 2004, 19:2729-2736.
140. Portis JL, Coe JE, et al. Deposition of IgA in renal glomeruli of mink affected with Aleutian disease. Am J Pathol 1979, 96:227-236.
141. Jessen RH, Emancipator SN, Jacobs GH, et al. Experimental IgA-IgG nephropathy induced by a viral respiratory pathogen. Dependence on antigen form and immune status. Lab Invest 1992, 67:379-386.
142. Schroeder C, Osman AA, Roggenbuck D, et al. IgA-gliadin antibodies, IgA-containing circulating immune complexes, and IgA glomerular deposits in wasting marmoset syndrome. Nephrol Dial Transplant 1999, 14:1875-1880.
143. Marquina R, Diez MA, Lopez-Hoyos M, et al. Inhibition of B cell death causes the development of an IgA nephropathy in (New Zealand white x C57BL/6)(F1bcl)-2 transgenic mice. J Immunol 2004, 172:7177-7185.
144. Kennel-De March A, Prin-Mathieu C, Kohler CH, et al. Back-pack mice as a model of renal mesangial IgA dimers deposition. Int J Immunopathol Pharmacol 2005, 18:701-708.
145. Frimat L, Kessler M Controversies concerning the importance of genetic polymorphism in IgA nephropathy. Nephrol Dial Transplant 2002, 17:42-45.
146. Johnstone DB, Holzman LB Clinical impact of research on the podocyte slit diaphragm. Nat Clin Pract Nephrol 2006, 2:271-282.
147. Helms C, Cao L, Krueger JG, et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003, 35:349-356.
148. Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
149. Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003, 35:341-348.
150. Hoogendoorn B, Coleman SL, Guy CA, et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet 2003, 12:2249-2254.
151. Lo HS, Wang Z, Hu Y, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003, 13:1855-1862.
152. Hsu SI The molecular pathogenesis and experimental therapy of IgA nephropathy: Recent advances and future directions. Curr Mol Med 2001, 1:183-196.
153. Izzi C, Sanna-Cherchi S, Prati E, et al. Familial aggregation of primary glomerulonephritis in an Italian population isolate: Valtrompia study. Kidney Int 2006, 69:1033-1040.
154. Julian BA, Quiggins PA, Thompson JS, et al. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 1985, 312:202-208.
155. Scolari F Inherited forms of IgA nephropathy. J Nephrol 2003, 16:317-320.
156. Schena FP, Cerullo G, Rossini M, et al. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 2002, 13:453-460.
157. Izzi C, Ravani P, Torres D, et al. IgA nephropathy: The presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis 2006, 47:761-769.
158. Li LS, Liu ZH Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies. Kidney Int 2004, 66:920-923.
159. Mittal BV, Singh AK, Rennke HG Spectrum of glomerular disease: Results of the Brigham database of glomerulonephritis. J Am Soc Nephrol 2004, 15:553A.
160. Hall YN, Fuentes EF, Chertow GM, et al. Race/ethnicity and disease severity in IgA nephropathy. BMC Nephrol 2004, 5:10.
161. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000, 26:354-357.
162. Tsukaguchi H A genetic mapping for a familial IgA nephropathy. Nephrology (Carlton) 2004, 9(Suppl 2):A65.
163. Schena FP, Cerullo G, Torres DD, et al. The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol 2005, 6:14.
164. Suzuki H, Suzuki Y, Yamanaka T, et al. Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol 2005, 16:1289-1299.
165. Oida E, Nogaki F, Kobayashi I, et al. Quantitative trait loci (QTL) analysis reveals a close linkage between the hinge region and trimeric IgA dominancy in a high IgA strain (HIGA) of ddY mice. Eur J Immunol 2004, 34:2200-2208.
166. Nogaki F, Oida E, Kamata T, et al. Chromosomal mapping of hyperserum IgA and glomerular IgA deposition in a high IgA (HIGA) strain of ddY mice. Kidney Int 2005, 68:2517-2525.
167. Schneider B, Hanke P, Jagla W, et al. Synergistic interaction of two independent genetic loci causes extreme elevation of serum IgA in mice. Genes Immun 2004, 5:375-380.
168. Schena FP, D'Altri C, Cerullo G, et al. ACE gene polymorphism and IgA nephropathy: An ethnically homogeneous study and a meta-analysis. Kidney Int 2001, 60:732-740.
169. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
170. Hunley TE, Julian BA, Phillips JA, et al. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996, 49:571-577.
171. Kunz R, Bork JP, Fritsche L, et al. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. J Am Soc Nephrol 1998, 9:1653-1663.
172. Poch E, Gonzalez D, Giner V, et al. Molecular basis of salt sensitivity in human hypertension. Evaluation of reninangiotensin-aldosterone system gene polymorphisms. Hypertension 2001, 38:1204-1209.
173. Goldstein DB Islands of linkage disequilibrium. Nat Genet 2001, 29:109-111.
174. Wahl JD, Pritchard JK Haplotype blocks and linkage disequilibrium in the human genome. Nat Rev Genet 2003, 4:587-597.
175. Couser WG Revisions to instructions to JASN authors regarding articles reporting studies using DNA arrays, DNA polymorphisms and randomized controlled clinical trials. J Am Soc Nephrol 2003, 14:2686-2687.
176. Takei T, Iida A, Nitta K, et al. Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet 2002, 70:781-786.
177. Takei T, Hiraoka M, Nitta K, et al. Functional impact of IgA nephropathy-associated selectin gene haplotype on leukocyte-endothelial interaction. Immunogenetics 2006, 58:355-361.
178. Li YJ, Du Y, Li CX, et al. Family-based association study showing that immunoglobulin A nephropathy is associated with the polymorphisms 2093C and 2180T in the 3' untranslated region of the Megsin gene. J Am Soc Nephrol 2004, 15:1739-1743.
179. Xia YF, Huang S, Li X, et al. A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. Clin Nephrol 2006, 65:153-159.
180. Schena FP, Cerullo G, Torres DD, et al. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: A family-based association study. Eur J Hum Genet 2006, 14:488-496.